GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies
GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of distinguished gene therapy expert, Nicole Paulk, PhD, to its Scientific Advisory Board (SAB).
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that it will present at the 2022 BIO CEO & Investor Conference.